Sleep hormone tested to halt debilitating MS progression
NCT ID NCT03540485
Summary
This study aimed to see if adding the hormone melatonin to the standard drug ocrelizumab could safely help slow down disability in people with a fast-progressing form of multiple sclerosis (MS). It involved 25 adults with primary progressive MS who were already stable on ocrelizumab. Participants took either melatonin or a placebo pill daily for two years while researchers tracked their disability, brain changes, and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Vithas Nisa Sevilla
Seville, Seville, 41950, Spain
-
Virgen Macarena Hospital
Seville, Seville, 41009, Spain
-
Virgen del Rocio University Hospital
Seville, Seville, 41013, Spain
Conditions
Explore the condition pages connected to this study.